REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells. The study will evaluate the use of REGN15505 when administered alone, in combination with cemiplimab, or in combination with REGN4336 for: * Any side effects of study drugs * How well the study drugs work * How much REGN15505, cemiplimab, and REGN4336 are in the blood at different times * If the body makes antibodies to REGN15505 or REGN4336, which may mean the study drugs will not work as well as expected * What is the best dose of REGN15505 when administered alone and with cemiplimab and the best dose of REGN15505 and REGN4336 when used in combination
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni z potwierdzonym rakiem gruczoławym prostaty bez małokomórkowego typu
- •Zaawansowany rak prostaty oporny na leczenie hormonalne z poziomem PSA ≥4 ng/mL i progresją w ciągu 6 miesięcy
- •Wcześniejsze leczenie co najmniej 2 innymi schematami terapii
- •Usunięte jądra lub leczenie hormonalne obniżające testosteron poniżej 50 ng/dL
- •Mężczyźni i kobiety z potwierdzonym rakiem nerki z przezroczystkokomórkowym składnikiem
- •Zaawansowany rak nerki z co najmniej jednym mierzalnym guzem
- •Wcześniejsza progresja na leczeniu immunoterapią (leczenie anty-PD-1/PD-L1) i/lub innymi lekami
✗ Disqualifies
- •Otrzymanie innego leku przeciwnowotworowego w ciągu 3 tygodni przed rozpoczęciem badania
- •Wcześniejsze leczenie lekami celowanymi na antygen PSMA (z wyjątkiem radioterapii radioligandowej)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
City of Hope Phoenix
Goodyear, United States
City of Hope
Duarte, United States
City of Hope Chicago, City of Hope Cancer Center Chicago
Zion, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Trial contact
Clinical Trials Administrator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.